Clinical trials: Early Breast Cancer
Breast Cancer (Early Breast Cancer), Sentinel Lymph Node Biopsy
NAUTILUS-04: No Axillary Surgical Treatment in Low-Risk Clinically Node-Negative Breast Cancer Without Whole-Breast Radiotherapy
The safety of omitting sentinel lymph node biopsy (SLNB) has been established only in patients undergoing breast-conserving surgery with whole-breast radiotherapy, as demonstrated in the prior randomized trials.
- Trial name
- NAUTILUS-04 (NCT07841704)
- Testing
- Omission of axillary surgery, Sentinel lymph node biopsy
- Where
- South Korea
- Volunteers
- 1,520 people
- Sponsor
- Wonshik Han
Aerobic Exercise, Early Stage Triple Negative Breast Cancer
Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC
To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.
- Trial name
- NCT07216495
- Testing
- Exercise
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Survivor, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Collaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication
The goal of this study is to learn about the impact of an integrated medication monitoring system in breast cancer survivors aged 21-70 who are prescribed endocrine therapy.
- Trial name
- NCT06865755
- Testing
- integrated medication monitoring (MM) system
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- San Diego State University
Breast Cancer (Early Breast Cancer)
Skipping Hormone Therapy in Low-Risk Early Breast Cancer
The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse.
- Trial name
- NoELA (NCT07661927)
- Testing
- Removing Endocrine Therapy
- Where
- 41 sites in France
- Volunteers
- 700 people
- Sponsor
- UNICANCER
Early Triple-Negative Breast Cancer
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
This multicenter phase II study evaluates a de-escalation strategy of neoadjuvant chemo-immunotherapy in patients with stage II early triple-negative breast cancer and tumor-infiltrating lymphocytes (TILs) ≥ 30%.
- Trial name
- DECREASE (NCT07857486)
- Testing
- Pembrolizumab
- Volunteers
- 84 people
- Sponsor
- Institut Paoli-Calmettes
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
ER+ Breast Cancer, Breast Cancer
Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence.
Hormone receptor-positive (HR+) breast cancers represent the most common histological subtype of breast cancer, accounting for approximately 75% of cases, regardless of HER2 (human epidermal growth factor receptor 2) status (1).
- Conditions
- ER+ Breast Cancer, Breast Cancer, Early Breast Cancer, Endocrine Therapy
- Trial name
- AdheRA (NCT07443774)
- Where
- France
- Volunteers
- 81 people
- Sponsor
- University Hospital, Grenoble
Breast Cancer (Early Breast Cancer)
ADC Based Therapy Accroding to HER2 Heterogeneous
This study adopts a single-center, open-label, single-arm interventional design. It will enroll 88 patients with histologically confirmed HER2-positive early breast cancer who are suitable for surgery and neoadjuvant therapy, and…
- Trial name
- HER2level (NCT07844018)
- Testing
- HER2 target therapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking University People's Hospital
HER2-positive Breast Cancer, Early Breast Cancer (EBC)
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage…
- Trial name
- NCT07856303
- Testing
- SHR-A1811, Trastuzumab, Pertuzumab
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Fudan University
Breast Neoplasms, Early Detection of Cancer
Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial
This multicenter, cluster randomized trial will evaluate whether community-based breast ultrasound screening improves the early detection of breast cancer in women aged 65 to 80 years, compared with routine health management.
- Trial name
- NCT07698366
- Testing
- Standardized Breast Ultrasound Screening
- Where
- 2 sites in China
- Volunteers
- 80,000 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer (Early Breast Cancer)
A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer
This is a multicenter, open-label, randomized controlled trial. A total of 432 eligible patients with HER2-positive breast cancer will be enrolled after screening.
- Trial name
- SwithADC (NCT07844291)
- Testing
- A1811, THP
- Volunteers
- 432 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Early-Stage Breast Carcinoma
SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers
SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume with a simultaneous integrated boost of 30 Gy to the clinical target…
- Conditions
- Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Trial name
- SOLIS (NCT07844759)
- Testing
- Stereotactic Radiation Therapy, Endocrine Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Renaissance Institute of Precision Oncology and Radiosurgery
Early-Stage Breast Cancer
1-Week Versus 3-Week PBI
This non-inferiority, phase 3 clinical trial evaluates the cosmetic non-inferiority of a one-week regimen (26 Gy/5 Fx) versus a three-week regimen (40 Gy/15 Fx) using intensity-modulated radiation therapy (IMRT) for partial…
- Trial name
- NCT07832279
- Testing
- 3-week PBI, 1-week PBI
- Where
- China
- Volunteers
- 818 people
- Sponsor
- Fudan University
Early-stage Invasive Lobular Breast Carcinoma
AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma
Invasive lobular breast carcinoma (ILC), the second most common breast cancer type, represents approximately 15% of all breast cancer cases.
- Trial name
- NCT07842055
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Early Breast Cancer
Artificial Intelligence (AI) - Based Models for Biomarkers Prediction
Despite the improvements in therapeutic approaches, breast cancer remains the most commonly occurring cancer and leading cause of cancer death in women worldwide.
- Trial name
- NCT07842068
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
This phase II trial tests reduced post surgery (adjuvant) therapy for patients with early breast cancer who have confirmed that the disease has responded completely (pathologic complete response) after pre surgical treatment…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07407920
- Testing
- Biospecimen Collection, Hormone Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Breast Cancer Early Stages, Ductal Carcinoma In Situ, DCIS
Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy
The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELL™) can improve positioning and patient comfort during prone radiotherapy (radiotherapy given while the patient lies on…
- Trial name
- SHIELD (NCT07711847)
- Testing
- VENUS SHELL™ immobilization device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- HeroSupport SA
This Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean Women in Real World
Community Study to Increase Mammogram Screening Among Overdue Women
Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective.
- Trial name
- IMPLEMENT (NCT07832396)
- Testing
- Evidence-based behavioural intervention
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Early Breast Cancer
Mediterranean Diet and Inequality in Early Breast Cancer
Social determinants such as education, income, marital status, and social networks play a crucial role in cancer outcomes, including breast cancer.
- Trial name
- MEDITERRACARE (NCT07007169)
- Testing
- The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food., Standard Diet
- Where
- 3 sites in Denmark
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER